Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

7Total
Not Applicable (1)
P 1 (3)
P 2 (2)
P 3 (1)

Trial Status

Recruiting4
Active Not Recruiting2
Withdrawn1

Clinical Trials (7)

Showing 7 of 7 trials
NCT06500481Phase 3Recruiting

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT04460937Phase 1Active Not Recruiting

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

NCT03696030Phase 1Active Not Recruiting

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

NCT05746325Not ApplicableRecruiting

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

NCT06518057Phase 2Recruiting

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

NCT06910761Phase 2Recruiting

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

NCT06137651Phase 1Withdrawn

Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

Showing all 7 trials

Research Network

Activity Timeline